1. Introduction

Antitrust in genomics refers to the application of competition law to the development, ownership, licensing, commercialization, and use of genomic technologies and genetic information. Its purpose is to prevent companies, research institutions, and other market participants from using market power to restrict competition, exclude rivals, inflate prices, or obstruct access to essential genetic testing and research resources.

Genomics involves the study of an organism’s complete genetic material. Commercial applications include:

Genetic testing for inherited diseases and cancer.

Genome sequencing and personalized medicine.

Gene–disease association databases and genomic reference datasets.

DNA sequencing instruments, reagents, and laboratory technologies.

Patents covering genetic diagnostic methods and genomic inventions.

Artificial intelligence systems trained on genomic information.

Licensing of genetic biomarkers and companion diagnostics for medicines.

Antitrust law becomes relevant when control over these resources gives an undertaking the ability and incentive to restrict competition. However, a patent, exclusive licence, large genomic database, or dominant market position is not automatically unlawful. The legal question is whether the conduct violates the applicable competition rules.

The principal challenge is balancing two objectives: protecting incentives to invest in expensive genomic research and ensuring that intellectual property rights do not become instruments for unlawfully excluding competitors.

2. Principal forms of antitrust concerns in genomics

A. Genomic patent monopolization

A company may own patents over sequencing techniques, genetic biomarkers, or diagnostic methods. Competition concerns can arise where the patent holder uses exclusionary licensing, coercive package licences, or other unlawful conduct to prevent competing technologies from entering the market.

B. Exclusive control over genetic testing

A laboratory that controls a commercially important test may refuse competing laboratories access to necessary technology or data. Whether such refusal violates antitrust law depends on the jurisdiction, the circumstances, and the existence of a legally cognizable exclusionary practice.

C. Genomic data monopolization

A firm may accumulate large datasets, proprietary variant databases, or sequencing records that are difficult for rivals to replicate. Network effects, switching costs, privacy restrictions, and exclusive data agreements may reinforce market power.

D. Mergers and acquisitions

Acquiring a competing genomic diagnostics business, sequencing platform, or promising biotechnology company may eliminate an important present or future competitor. Merger review examines the likely effects on prices, innovation, research incentives, and market entry.

3. Leading case laws and their legal significance

Case 1: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

569 U.S. 576 (2013) · United States Supreme Court

Facts: Myriad Genetics identified the locations and sequences of the BRCA1 and BRCA2 genes associated with increased risks of breast and ovarian cancer. It obtained patents relating to those genes and developed genetic tests. The patent claims raised concerns about whether others could independently study or test the same genes.

Legal issue: Could naturally occurring human DNA sequences be patented merely because they had been isolated from the human body?

Decision: The Supreme Court held that naturally occurring DNA is not patent-eligible merely because it has been isolated. Synthetically created complementary DNA (cDNA) may be patent-eligible, subject to the applicable requirements. The Court did not decide a general antitrust claim.

LII / Legal Information Institute

+1

Antitrust significance:

It limited one potential source of exclusionary control over naturally occurring genetic sequences.

It preserved room for patent protection over qualifying inventions, including certain synthetic genetic materials.

It illustrates the distinction between patent eligibility and antitrust liability.

The decision did not establish that Myriad had violated antitrust law. Rather, it addressed the patent-law foundation on which certain forms of exclusivity might depend.

Case 2: Illumina, Inc. v. European Commission (2024)

Joined Cases C-611/22 P and C-625/22 P, ECLI:EU:C:2024:677

Facts: Illumina, a major provider of genetic sequencing technology, acquired GRAIL, a company developing blood tests for early cancer detection. The European Commission sought to examine the transaction despite the transaction not meeting the relevant EU or national merger thresholds.

Legal issue: Could the Commission accept referrals under Article 22 of the EU Merger Regulation from national competition authorities that lacked competence under their own national laws to review the transaction?

Decision: On 3 September 2024, the Court of Justice of the European Union set aside the General Court's judgment and annulled the Commission's referral decisions. It held that the Commission could not accept those referrals from authorities lacking the requisite national competence.

EUR-Lex

+1

Antitrust significance:

Genomics mergers may raise concerns about control over sequencing infrastructure and emerging diagnostic markets.

Competition authorities must nevertheless possess a lawful basis to review a transaction.

Innovation-related competition concerns do not remove procedural and jurisdictional limits.

Merger review must distinguish the substantive risk of reduced competition from the authority's legal power to investigate.

Important qualification: This judgment concerned the Commission's jurisdiction to examine the merger through the referral mechanism. It was not a final judicial finding that the acquisition substantively violated competition law. The Commission subsequently withdrew its merger decisions following the judgment, and Illumina completed the divestment of GRAIL in June 2024.

ILLUMINA / GRAIL

+1

Case 3: United States v. Microsoft Corp. (2001)

253 F.3d 34 (D.C. Cir. 2001) (en banc)

Facts: Microsoft faced antitrust proceedings concerning its use of its operating-system position and practices affecting competing browser technologies.

Legal principle: The case addressed monopolization and exclusionary conduct under Section 2 of the Sherman Act. It distinguished lawful success in the marketplace from conduct that maintains monopoly power through unlawful exclusion.

Application to genomics: Although not a genomics case, its reasoning can help analyze a genomic platform that controls an important sequencing ecosystem, diagnostic interface, or bioinformatics infrastructure and uses exclusionary agreements to disadvantage rivals.

For example, a platform might make access to its sequencing system conditional on laboratories using only its proprietary analysis software. The arrangement would require factual analysis of market power, competitive effects, business justification, and applicable law; exclusivity alone would not automatically establish a violation.

Case 4: Aspen Skiing Co. v. Aspen Highlands Skiing Corp. (1985)

472 U.S. 585 (1985)

Facts: A dominant ski operator discontinued a previously profitable joint ticketing arrangement with a smaller rival, even though doing so involved sacrificing short-term economic benefits.

Legal principle: Under the particular circumstances, the Supreme Court upheld liability for exclusionary monopolization. The decision is important to the narrow question of when a monopolist's refusal to cooperate with a rival can violate antitrust law.

Application to genomics: Imagine a dominant genomic laboratory that previously supplied a rival with a necessary testing service on commercial terms, then terminates the arrangement to eliminate the rival rather than for a legitimate operational reason.

Aspen Skiing may be relevant, but it does not establish a general duty to share genomic data or technology. Modern courts apply restrictive standards to refusal-to-deal claims, and the availability of alternatives and the commercial context matter.

Case 5: Verizon Communications Inc. v. Law Offices of Curtis V. Trinko, LLP (2004)

540 U.S. 398 (2004)

Facts: The dispute concerned alleged failures by a telecommunications incumbent to provide competitors with access required under a regulatory framework.

Legal principle: The Supreme Court emphasized that antitrust law generally does not impose a broad duty on firms to assist their competitors. It treated the Aspen Skiing exception narrowly.

Application to genomics: A company holding a large genomic dataset is not automatically required by antitrust law to license it to every competing laboratory. A claim must establish more than the dataset's usefulness or the owner's market strength.

This case is particularly important when considering proposed mandatory data-sharing rules: a legislature or regulator may create access obligations, but the existence of such an obligation should not be assumed from general antitrust principles alone.

Case 6: FTC v. Actavis, Inc. (2013)

570 U.S. 136 (2013)

Facts: The case concerned agreements in which brand-name pharmaceutical companies made payments to generic manufacturers in connection with settlements of patent litigation.

Decision: The Supreme Court held that such agreements could be examined under the rule of reason under federal antitrust law. A patent does not automatically immunize all commercial agreements related to it.

Application to genomics: The principle may be relevant where genomic diagnostic patent holders enter licensing or settlement arrangements that delay competing tests or restrict entry. However, the case did not involve genomic patents, and any application to genomics would depend on the actual agreement and its competitive effects.

4. Main legal theories of antitrust liability

These theories are jurisdiction-specific. For example, US monopolization law under Section 2 of the Sherman Act and Indian abuse-of-dominance law under Section 4 of the Competition Act, 2002, are not interchangeable.

5. Antitrust regulation of genomics in India

India's principal framework is the Competition Act, 2002, administered by the Competition Commission of India (CCI). The framework prohibits anticompetitive agreements, abuse of dominant position, and combinations that cause or are likely to cause an appreciable adverse effect on competition in India.

Competition Commission of India

+1

A. Section 3 — Anti-competitive agreements

Section 3 applies to agreements that cause or are likely to cause an appreciable adverse effect on competition in India.

In genomics, potential concerns include:

Competing genetic-testing laboratories agreeing to fix diagnostic prices.

Sequencing companies dividing geographic markets or allocating hospital customers.

Competitors coordinating to restrict the supply of sequencing services.

Restrictive licensing or distribution agreements that materially harm competition.

Section 3 also addresses vertical restraints, including exclusive arrangements and tying. Their legality depends on the statutory framework and the effects of the arrangement. Section 3(5) contains an intellectual-property-related exception for reasonable conditions necessary to protect specified rights; it is not a blanket immunity for every patent licence.

Competition Commission of India

+1

B. Section 4 — Abuse of dominant position

Section 4 prohibits abuse of a dominant position, rather than dominance itself. The relevant provisions address unfair or discriminatory conditions or prices, restrictions on production or technical development, denial of market access, certain supplementary contractual obligations, and leveraging dominance from one market into another.

IndiaCode

+1

Consider a hypothetical company that controls a particularly important sequencing platform and makes hospitals purchase an unrelated proprietary analytics service to obtain sequencing access. If the company is dominant in a properly defined relevant market and the arrangement satisfies the statutory elements of abusive tying or leveraging, Section 4 may become relevant.

The analysis would require evidence about market definition, competing platforms, customer alternatives, entry barriers, contractual terms, and competitive effects.

C. Sections 5 and 6 — Combinations and mergers

These provisions govern qualifying mergers, acquisitions, and amalgamations.

A proposed acquisition of a genomics start-up may require scrutiny where it removes a significant present or potential competitor, consolidates control over sequencing infrastructure, or reduces incentives to develop competing diagnostic technologies. The precise notification requirements and exemptions must be assessed under the law in force at the transaction date.

IndiaCode

+1

6. Additional Indian case laws relevant to genomics

The following Supreme Court decisions establish competition-law principles that may be relevant to genomic markets. They are not direct rulings on genomics.

1. Competition Commission of India v. Steel Authority of India Ltd. (2010)

Citation: (2010) 10 SCC 744.

The Supreme Court examined the CCI's statutory powers and the legal character of its initial investigation process.

Relevance: Genomics-related complaints concerning exclusionary licensing or restricted diagnostic access must proceed through the appropriate statutory investigation and decision-making process. Allegations alone do not establish a competition violation.

2. Excel Crop Care Ltd. v. Competition Commission of India (2017)

Citation: (2017) 8 SCC 47.

The case concerned bid rigging in a public procurement market. The Supreme Court considered the statutory prohibition and the principles relevant to penalties.

Relevance: If genomic laboratories or biotechnology suppliers collude in tenders for public hospitals, research institutions, or government sequencing programmes, the case offers relevant guidance on cartel enforcement and penalties. It does not concern genetic testing directly.

3. CCI v. Bharti Airtel Ltd. (2019)

Citation: (2019) 2 SCC 521.

The Court addressed the relationship between sector-specific regulatory functions and the CCI's competition jurisdiction in a telecommunications dispute.

Relevance: Genomics can involve overlapping regulatory regimes, including competition, patent, privacy, medical-device, and health regulation. The case is useful when considering how competition investigations interact with a sector regulator's technical responsibilities, although the regulatory context differs.

These Indian cases provide procedural and substantive analogies. They should not be cited as judicial findings that a genomic company has committed an antitrust violation.

7. Genomic data, privacy, and competition

Genomic data raises a distinctive issue: data can be commercially valuable without being freely transferable.

A large genomic dataset may provide advantages through scale, statistical diversity, longitudinal observations, or integration with clinical outcomes. A competitor may struggle to reproduce these resources. Yet data access can be constrained by informed-consent terms, confidentiality, research agreements, security requirements, and applicable privacy law.

Competition authorities should distinguish between:

Lawful data protection: restricting access to protect participants, comply with law, or preserve legitimate confidentiality.

Potential exclusionary conduct: selectively denying access, imposing discriminatory conditions, or using exclusive arrangements to foreclose competition without adequate justification.

Regulatory access obligations: requirements imposed by legislation, a regulator, or a valid contractual commitment.

A competition remedy should not require disclosure of identifiable genetic information merely because a dataset is commercially important. Where access is justified, privacy-preserving methods, controlled research environments, and secure data-sharing arrangements may be more appropriate.

8. Remedies and enforcement

Depending on the jurisdiction and proven infringement, possible responses include:

Cease-and-desist orders: stopping unlawful exclusionary conduct or anticompetitive agreements.

Licensing remedies: correcting unlawful licensing restrictions or discriminatory access conditions where legally appropriate.

Merger remedies: prohibiting a transaction, requiring divestiture, or imposing suitable conditions under the applicable merger regime.

Financial penalties: imposing penalties where authorized by the governing statute.

Private legal remedies: damages or other relief where the relevant legal system provides them and the claimant satisfies the applicable requirements.

Compliance programmes: reviewing exclusivity, pricing, licensing, data access, and information exchange with competitors.

Remedies should address the proven competition harm without unnecessarily undermining research incentives, patient confidentiality, or legitimate intellectual-property protection.

9. Practical hypothetical

Suppose Genomic Innovations Ltd. controls a sequencing platform used by most specialist laboratories in a particular country. It introduces three practices:

It refuses to supply compatible reagents to an independent diagnostic laboratory.

It requires hospitals purchasing sequencing equipment to buy an unrelated analytics package.

It acquires a start-up developing an alternative sequencing technology.

Each practice requires a separate analysis.

Under Indian law, Sections 3, 4, 5, and 6 may be relevant depending on the facts and applicable thresholds. In the United States, the Sherman Act and Clayton Act may apply. In the European Union, Articles 101 and 102 TFEU and the EU Merger Regulation may be relevant.

No violation can be concluded from the hypothetical facts alone.

10. Conclusion

Antitrust in genomics seeks to preserve competitive markets for genetic testing, sequencing infrastructure, genomic databases, and biotechnology innovation. It must protect competition without treating every patent, exclusive arrangement, or large dataset as unlawful.

The key lessons from the case law are:

Myriad Genetics distinguishes patent eligibility from antitrust liability.

Illumina/GRAIL demonstrates the importance of lawful merger-review jurisdiction.

Microsoft illustrates the distinction between lawful market success and exclusionary monopolization.

Aspen Skiing and Trinko show why refusal-to-deal claims require careful, jurisdiction-specific analysis.

Indian competition legislation provides tools to address anticompetitive agreements, abuse of dominance, and harmful combinations, while Indian Supreme Court cases supply relevant procedural and enforcement principles.

Ultimately, effective regulation must protect innovation, promote meaningful competition, support affordable diagnostic access, and safeguard the legitimate rights of genomic data contributors.

Academic note: The authorities discussed above include both direct genomics-related patent or merger proceedings and general antitrust precedents applied by analogy. The latter should not be represented as genomics-specific judgments.